Evidence map›Paper›PMID 16121692›Full record

ReviewCurrent opinion in investigational drugs (London, England : 2000)2005

SPK-843 (Aparts/Kaken).

Noer Kasanah, Mark T Hamann

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in investigational drugs (London, England : 2000), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Noer KasanahDepartment of Pharmacognosy, National Center for Natural Product Research, School of Pharmacy, The University of Mississippi, MS 38677, USA.
Mark T Hamann
University of Mississippi · US

Funding

ANTIAIDS AGENTS FROM MARINE ORGANISMSR01AI036596 · NIAID · UNIVERSITY OF MISSISSIPPI · PI HAMANN, MARK T · 2001 to 2007
$2.3M
NIAID NIH HHS R01 AI036596
6 · The paper itself

Abstract

SPK-843 is a water-soluble antibiotic under co-development by Aparts and Kaken for the potential treatment of systemic fungal infections. By November 2004, SPK-843 was in phase II trials for systemic mycosis.

Indexed as

AnimalsAntifungal AgentsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicHumansMycosesPatents as TopicPolyenesStructure-Activity RelationshipAntifungal AgentsPolyenesSPA S 843

Identifiers

PMID16121692
PMCPMC4928195
OpenAlexW2409883444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.